Formycon Says Co & MS Pharma Sign Exclusive Commercialization Partnership For Keytruda® Biosimilar Candidate FYB206 For MENA Region
I'm PortAI, I can summarize articles.
Formycon AG :EQS-NEWS: FORMYCON AND MS PHARMA SIGN EXCLUSIVE COMMERCIALIZATION PARTNERSHIP FOR KEYTRUDA® BIOSIMILAR CANDIDATE FYB206 FOR THE MENA REGIONFORMYCON : WILL RECEIVE UPFRONT REMUNERATION & WILL BE ELIGIBLE FOR FURTHER PAYMENTS CONTINGENT ON ACHIEVEMENT OF CERTAIN MILESTONES
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments